Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Dimitrios MakrakisRafee TalukderLeonidas N DiamantopoulosLucia Carril-AjuriaDaniel CastellanoIvan De KouchkovskyVadim S KoshkinJoseph J ParkAjjai AlvaMehmet A BilenTyler F StewartRana R McKayVictor S SantosNeeraj AgarwalJayanshu JainYousef ZakhariaRafael Morales-BarreraMichael E DevittMichael GrantMark P LythgoeDavid J PinatoAriel NelsonChristopher J HoimesEvan ShreckBenjamin A GartrellAlex SankinAbhishek TripathiRoubini ZakopoulouAristotelis BamiasJure MurgicAna FröbeAlejo Rodriguez-VidaAlexandra DrakakiSandy LiuVivek KumarGiuseppe Di LorenzoMonika JoshiPedro Isaacsson-VelhoLucia Alonso BuznegoIgnacio DuranMarcus MosesPedro BarataGuru SonpavdeEvan Y YuJonathan L WrightPetros GrivasAli Raza KhakiPublished in: BJU international (2021)
Prior RS before developing advanced disease was associated with better outcomes in patients with aUC treated with ICIs in the second-plus-line but not in the first-line setting. While further validation is needed, our findings could have implications for prognostic estimates in clinical discussions and benchmarking for clinical trials. Limitations include the study's retrospective nature, lack of randomization, and possible selection and confounding biases.